Hedgehog Pathway Inhibitors against Tumor Microenvironment.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Hedgehog (HH) pathway targeting has been explored for aggressive cancers for decades.
• HH pathway inhibitors have achieved FDA approval, but clinical success is limited in metastatic or recurrent diseases due to resistance and tumor microenvironment (TME) challenges.
• Reported side effects include hyponatremia, diarrhea, fatigue, and weight loss.

Purpose of the Study:

• To review the advantages and disadvantages of targeting HH signaling molecules.
• To elucidate mechanisms of treatment resistance in HH-driven cancers.
• To explore the role of the HH pathway in anti-tumor immunity and potential combination therapies.

Main Methods:

• Literature review of HH pathway inhibitors in cancer treatment.
• Analysis of mechanisms underlying treatment resistance.
• Investigation of HH pathway's role in TME and immune response.

Main Results:

• Clinically approved HH pathway inhibitors face limitations due to acquired resistance and TME interactions.
• HH signaling influences immune cell maturation, angiogenesis, inflammation, and immune suppressor cell polarization.
• Understanding HH's control over TME is crucial for developing novel therapeutic strategies.

Conclusions:

• Targeting the HH pathway requires strategies to overcome resistance and manage side effects.
• Combination therapies, particularly with immune checkpoint inhibitors, hold potential for treating HH-driven cancers.
• Further research into HH's role in TME and anti-tumor immunity is critical for clinical advancement.